Cutting-Edge Gene Editing
with GMP Ready iPSCs

As a CRO/CDMO, our goal is to transform your need for allogenic cell therapy manufacturing, disease
modeling, and drug discovery. We achieve this through our unique gene editing
platforms, which offer a clear IP path to commercialization. Complementing this,
we have state-of-the-art stem cell generation and differentiation technologies, and
advanced high-throughput antibody/biologic screening.